PBA
INSM icon

Paradigm Biocapital Advisors’s Insmed INSM Stock Holding History

Paradigm Biocapital Advisors’s Portfolio INSM Stock Details INSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$205M Buy
+1,254,488
New +$193M 4.19% 7
2025
Q2 		– Sell
-451,359
Closed -$34.4M – 33
2025
Q1 		$34.4M Buy
+451,359
New +$34.5M 1.58% 17
2022
Q1 		– Sell
-394,358
Closed -$10.7M – 29
2021
Q4 		$10.7M Buy
+394,358
New +$11.3M 3.07% 13

Other funds holding INSM

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Paradigm Biocapital Advisors's INSM Position: Q1 2026 in Review

Paradigm Biocapital Advisors opened a new position in Insmed (INSM) in Q1 2026: 1,254,488 shares worth $205M. The stake represents 4.19% of the portfolio and ranks #7 among its holdings. This is a return to the name: Paradigm Biocapital Advisors previously reported a position in INSM as recently as Q1 2025.

Paradigm Biocapital Advisors first reported a position in INSM in Q4 2021 and has held it in 3 quarters since. 669 funds tracked by Wall St. Rank hold INSM as of Q1 2026.

  • Paradigm Biocapital Advisors held 1,254,488 shares of Insmed worth $205M as of Q1 2026.
  • Insmed was a new Paradigm Biocapital Advisors position in Q1 2026.
  • Insmed made up 4.19% of Paradigm Biocapital Advisors's portfolio in Q1 2026, its #7 holding.
  • Paradigm Biocapital Advisors first reported a position in Insmed in Q4 2021 and has held it in 3 quarters since.
  • 669 funds tracked by Wall St. Rank held Insmed as of Q1 2026.

Based on Paradigm Biocapital Advisors's 13F filing for Q1 2026, filed 15 May 2026.